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Aim: To investigate the association between ACE gene I/D polymorphism and thyroid-associated ophthalmopathy (TO) in the Turkish
population.
Materials and methods: A total of 105 patients with TO and 102 healthy control subjects were enrolled in this case-control study.
Genomic DNA was extracted from peripheral blood leukocytes, and I/D polymorphism of the ACE gene (ACE) was determined using
a polymerase chain reaction.
Results: There were no marked changes in allelic frequencies and genotype distribution of ACE I/D polymorphism between patients
and control subjects. The distribution of I/D polymorphism and allele frequencies of TO patients were not significantly different from
those of the controls: DD genotype 34.3% vs. 41.2%; ID genotype 46.7% vs. 43.1%; and II genotype 19.0% vs. 15.7%; D allele 57.6% vs.
62.7%; I allele 42.4% vs. 37.3% (P > 0.05). Genotype and allele frequencies for men and women were also similar between the groups.
Conclusion: Our data suggest that ACE gene I/D polymorphism does not constitute a risk factor for TO in the Turkish population.
Further studies using greater numbers of patients from different populations are required to clarify the role of the ACE gene in
conferring susceptibility to TO.
Key words: ACE gene, allele frequency, I/D genotype, polymorphism, thyroid-associated ophthalmopathy

1. Introduction
Thyroid-associated ophthalmopathy (TO), also called
ophthalmic Graves’ disease, Graves’ ophthalmopathy,
Graves’ orbitopathy, or thyroid eye disease, is considered
an autoimmune disease based on a heterogeneous genetic
disorder, but despite extensive research performed on the
topic, its causative effects are still not fully understood.
TO patients are not strictly hyperthyroid, but a minority
of patients (around 10% or less) are euthyroid or
hypothyroid (1). As for other autoimmune diseases, a
number of environmental and genetic factors are thought
to be involved in the pathogenesis of TO (2). Among
environmental factors, iodine, drugs (e.g., amiodarone),
stress, and smoking are known to play roles in the
pathogenesis of TO. TO is seen most frequently in relatives
of TO patients. It is documented that candidate genes
including human leukocyte antigen (HLA), cytotoxic
T-lymphocyte antigen-4 (CTLA-4), tumor necrosis factor-a
* Correspondence: seydiokumus@hotmail.com
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(TNF-a), interferon-g (IFN-g), intercellular adhesion
molecule-1 (ICAM-1), and thyroid-stimulating hormone
receptor (TSHR) play roles in the pathogenesis of TO (3).
In orbital soft tissue, TO-induced chronic inflammation
leads to edema, glucosaminoglycan synthesis, proliferation
of fibroblasts and adipocytes (early phase), and fibrosis
(late phase). These events can then cause sight-altering
phenomena (e.g., elevation of orbital pressure, proptosis,
dry eye syndrome, exposure keratopathy, optic neuropathy,
fibrotic lid retraction, forward displacement of the eyeball,
and diplopia) to occur (4). The incidence of TO has been
reported to vary from 30% to 60% among races (2,5).
TO occurs in about 40%–50% of cases of Graves’ disease,
and is sight-threatening (because of optic neuropathy or
corneal ulceration) in 3%–5% (5).
Angiotensin I-converting enzyme (ACE) is a
carboxypeptidase that plays a central role in the renin–
angiotensin system (RAS) by catalyzing the conversion
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of angiotensin I to vasoactive angiotensin II (6). ACE
also affects the kinin–kallikrein system by inactivating
bradykinin, a peptide known to induce vasodilation
(6,7). Most of the recognized RAS components have
already been detected in the human eye (8). In addition
to circulatory RAS, there is a tissue-localized system, and
local RAS may have a significant role in the formation of
aqueous humor and also in its drainage (8). The encoding
gene ACE in humans is located on 17q23, which is 21 kb in
length, and includes 26 exons and 25 introns. Rigat et al. (9)
identified a polymorphism in the ACE gene characterized
by the insertion (I) or deletion (D) of a 287 base pair alu
repeat sequence within intron 16. This polymorphism
has consistently been associated with approximately 45%
of the variance of serum ACE concentrations (9). Subject
with the DD genotype have been found to have ACE levels
twice as high as subjects carrying the II genotype (9). It
has also been hypothesized that the up-regulation of the
RAS system in hyperthyroidism and the increase in serum
and tissue angiotensin II level may activate the synthesis
of transforming growth factor-b (TGF-b), consequently
resulting in hyaluronic acid accumulation in the orbital
tissue (10). The purpose of this study was to test a possible
association between ACE I/D polymorphism and TO in a
Turkish population.
2. Materials and methods
2.1. Study population
A total of 105 patients with TO, diagnosed between
December 2007 and December 2011, and 102 healthy
persons were enrolled in this case-control study. The TO
patients comprised 40 men and 65 women, aged 20–70
years (average age 42.17 ± 10.14 years). The healthy
control subjects consisted of 50 men and 52 women, aged
31–57 years (average age 39.84 ± 10.40 years, P = 0.1042).
The study was approved by the local Ethics Committee,
and it was conducted in accordance with the Declaration
of Helsinki. All study participants gave informed consent.
The patient group comprised individuals diagnosed
with TO of at least 6 months’ duration. Patients who
had mild-to-moderate exophthalmoses, whose orbital
soft tissue and extra-ocular muscles were affected, as
documented by orbital magnetic resonance imaging, and
whose illnesses were controlled medically, were included in
this study. Ophthalmology grading was done according to
the NOSPECS classification (11). No patient had a history
of any corneal or optic nerve involvement, or prior orbital
decompression surgery. Other than TO, no autoimmune
or endocrine diseases were present in the patient group.
The control group comprised persons who had been
referred to the outpatient service for a variety of conditions,
including myopia, strabismus, and cataract. Persons

with existing allergic/autoimmune diseases, e.g., asthma,
systemic lupus erythematosus, rheumatoid arthritis, and
multiple sclerosis, were excluded from the study. Both
the patients and control subjects were all Caucasian and
Turkish descendants. None of the participants were related.
2.2. DNA isolation and genotyping
From all subjects, peripheral blood samples (5 mL) were
collected by venipuncture into sterile siliconized Vacutainer
tubes with 2 mg/mL disodium ethylenediaminetetraacetic
acid. Immediately after collection, whole blood was
stored at –20 °C until use. Genomic DNA was extracted
from whole blood by standard proteinase K digestion
and the salt–chloroform method (12), and stored at –20
°C. Analysis of the polymorphism of the ACE gene was
performed as described previously (13). Both TO patients
and control group subjects were analyzed for ACE I/D
polymorphism using the polymerase chain reaction (PCR).
The PCR products were visualized by electrophoresis in a
2% agarose gel with ethidium bromide and documented
with a gel documentation system (Vilber-Lourmar,
Eberhardzell, Germany) (Figure).
2.3. Statistical analysis
Results are expressed as the mean ± SD or percentage.
Statistical analysis was performed using GraphPad Instat
(version 3.05, GraphPad Software Inc., San Diego, CA,
USA) statistical software. Polymorphisms were tested for
deviation from Hardy–Weinberg equilibrium by comparing
the observed and expected genotype frequencies using
the chi-square test. For calculation of the significance of
differences in genotype and allele frequencies, the chisquare test (with Yate’s correction) or Fisher’s exact test
was used. The effects of genetic polymorphism on the risk
of TO development were estimated by an odds ratio (OR)
and its 95% confidence interval (CI). All statistical tests
and P values were 2-sided, and P < 0.05 was considered to
be statistically significant.
DD

II

ID

M

561
376
264

Figure. Agarose gel electrophoresis results. D allele reveals a
band at 274 bp, and I allele reveals a 561 bp band. DNA fragment
sizes, in bases, are indicated by numbers on right. M: size marker.
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3. Results
The genotype distributions of ACE I/D polymorphism
did not deviate from those predicted by Hardy–Weinberg
equilibrium among cases (P = 0.961 for the TO group) and
controls (P = 0.837). ACE genotype and allele distribution
patterns for both groups are shown in the Table. Carriers of
the DD, ID, and II genotypes were not found significantly
more often among patients with TO than among control
subjects. Similarly, no significant differences in the D
or I allele frequencies of ACE I/D polymorphism were
observed between patients and control subjects (Table).
Subgroup analysis related to sex revealed no significant
differences in the genotype and allele frequencies between
patients and control subjects (Table).
4. Discussion
Numerous studies have previously investigated ACE I/D
polymorphism as a potential risk factor for cardiovascular
and endocrine diseases (14,15). Yet to the best of our
knowledge, the present study is the first to evaluate the role
of this polymorphism in patients with TO. No statistically
significant association between TO and ACE I/D
polymorphism was demonstrated. Our findings suggest
that ACE I/D polymorphism was not involved in the TO
pathogenesis for the Turkish population.
It is known that angiotensin II augments vascular
permeability by stimulating the synthesis of vasoactive

substances, e.g., vascular endothelial growth factor,
leukotriene C4, prostaglandin E2, and prostaglandin I2
(16,17). Angiotensin II also elevates the adhesion of
macrophages and neutrophils to endothelial cells, and
has a direct effect on chemotaxis, proliferation, and
differentiation of immune system cells (17,18). Thus,
angiotensin II is a potent and active pro-inflammatory
mediator in the inflammatory cell infiltration of target
cells/tissues in the continuum of the immune response (18).
Signs and symptoms of TO also occur as a consequence
of inflammation of the orbital connective/fatty tissue and
soft-tissue enlargement in the orbit, leading to increased
pressure within the bony cavity, inflammation with the
production of cytokines and fibrosis of the extraocular
muscles, and adipogenesis (19). ACE activity is known to
be influenced by thyroid function at both the circulating
and tissue levels. Hyperthyroid patients have shown an
increase in serum ACE concentrations and activity that is
positively correlated with thyroid hormone levels (20). The
rate of preoperative high serum thyroid hormone levels
was significant in patients with a benign thyroid pathology
(21). Collectively, these data suggest that serum ACE levels
increase during hyperthyroidism, and there is a strong
correlation between ACE activity and thyroid hormone
concentrations.
The volumes of both the extra-ocular muscles and
retro-orbital connective and adipose tissues are increased,

Table. Genotype and allele frequencies of ACE I/D polymorphism in all patients with TO and controls. Frequencies according to sex
are also shown.
Genotypes/ Alleles

Controls
(n = 102) n (%)

Patients with OT
(n = 105) n (%)

DD
ID
II
D
I

42 (41.2)
44 (43.1)
16 (15.7)
128 (62.7)
76 (37.3)

36 (34.3)
49 (46.7)
20 (19.0)
121 (57.6)
89 (42.4)

Female

(n = 52) n (%)

(n = 65) n (%)

DD
ID
II
D
I
Male
DD
ID
II
D
I

24 (46.2)
19 (35.5)
9 (17.3)
67 (64.4)
37 (35.6)
(n = 50) n (%)
18 (36.0)
25 (50.0)
7 (14.0)
61 (61.0)
39 (39.0)

20 (30.8)
31 (47.7)
14 (21.5)
71 (54.6)
59 (45.4)
(n = 40) n (%)
16 (40.0)
18 (45.0)
6 (15.0)
50 (62.5)
30 (37.5)

OR, odds ratio; CI, confidence interval
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P value

OR (95% CI)

0.485
0.464

1.299 (0.711–2.375)
1.458 (0.659–3.227)

0.335

1.239 (0.835–1.838)

0.162
0.305

1.958 (0.859–4.462)
1.867 (0.669–5.211)

0.167

1.505 (0.886–2.556)

0.822
1.000

0.810 (0.327–2.004)
0.964 (0.268–3.475)

0.959

0.939 (0.512–1.719)
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due to inflammation and the accumulation of hydrophilic
glycosaminoglycans, principally hyaluronic acid, in these
tissues (4,5). The accumulation of glycosaminoglycans
induces a change in osmotic pressure, which in turn
leads to a fluid accumulation and an elevation in pressure
within the orbit and displace the eyeball forward in TO
(4,5). Since components of the RAS system are localized in
the human ocular tissues (8), and angiotensin II potently
induces synthesis of transforming growth factor TGF-b
(22), it is likely that increased angiotensin II levels may
activate synthesis of TGF-b and then stimulate hyaluronic
acid accumulation in the orbital tissue, as hypothesized
by Sagheb et al. (10). There is also evidence that the
inflammatory mediator TNF-a induces the formation of
fibrotic foci by cultured retinal pigment epithelial cells
through activation of TGF-b signalling (23), and serum
TNF-a values are known to be increased in patients with
hyperthyroidism (24).
It is known that thyroid-associated ophthalmopathy is
more frequent in women (16 cases/100,000 people/year)
than in men (3 cases/100,000 people/year) (25). We have
also observed a high frequency of women patients in our
study.
It is documented that ACE polymorphisms affect
serum ACE levels and, thus, RAS activity and efficiency.
The DD genotype and D allele of the ACE gene have been

shown to be associated with higher enzymatic activity and
expression (9). On the other hand, the I allele of the ACE
gene has been shown to be associated with lower ACE
activity and kinin degradation (26). However, we did not
measure ACE enzyme activity or expression in this study.
It is known that ACE gene allele distributions vary
greatly among different populations. The prevalence of
the ACE gene polymorphism D allele is 39% in Japanese,
54% in European Caucasian, 56% in American Caucasian,
and 60% in African American (27,28) populations. Our
population consisted of Turkish Caucasians, and the
genotype and allele frequencies found in this study were
similar to the previously reported frequencies in Turkish
populations (29,30). The D allele frequency has been
reported to be 60.1% (29) or 64.0% (30) in healthy Turkish
populations. We found a D allele frequency of 62.7% in the
present study, which appears to be similar to the reported
frequencies.
In conclusion, ACE I/D polymorphism is not a risk
factor for TO in the Turkish population. The lack of
association of ACE I/D genotypes and alleles between
TO patients and control subjects leads us to exclude any
possible relationship between ACE I/D polymorphism and
TO. Studies in larger populations are needed to confirm
these results in TO, and further studies are required to
verify these findings in different ethnic groups.
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